Immunomonitoring of MSC-Treated GvHD Patients Reveals Only Moderate Potential for Response Prediction but Indicates Treatment Safety
暂无分享,去创建一个
J. Partanen | U. Salmenniemi | M. Itälä-Remes | J. Nystedt | M. Korhonen | T. Kaartinen | A. Hänninen | J. Castrén | K. Lähteenmäki | J. Keto